Navigation Links
Syndax Pharmaceuticals Elects Arlene Morris to Board of Directors
Date:6/8/2011

WALTHAM, Mass., June 8, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, announced that Arlene Morris has been elected to the board of directors.  Ms. Morris most recently was the chief executive officer and a member of the board of directors of Affymax, Inc., a biopharmaceutical company that was spun out of GlaxoSmithKline (GSK) in 2001 to develop a pipeline of synthetic peptide-based drug candidates for the treatment of anemia in dialysis patients.  

"Arlene is bringing to Syndax extensive biotechnology and pharmaceutical experience in general management, marketing, sales, business development and strategic marketing," said Dennis Podlesak, chairman of the Syndax board of directors.  "With entinostat entering a phase 3 program this is a great time for Arlene to leverage her extensive experience and provide guidance as we are moving in to the final stages of clinical development."

"I am excited to join the board as Syndax moves into pivotal trials with entinostat in women with metastatic breast cancer, an area where resistance poses an ongoing problem," said Ms. Morris.  "Syndax provides a great opportunity for me to contribute to the direction of a company with a promising oncology pipeline aimed at improving survival outcomes with a non-chemotherapy option."

During her eight years as president and CEO at Affymax, Ms. Morris led the company through the development of peginesatide (Hematide™), a strategic collaboration with Takeda and an Initial Public Offering.  Prior to Affymax Ms. Morris was the president and CEO of Clearview Projects, an advisory firm which counsels biopharmaceutical and biotechnology companies on strategic transactions. Before that she was the senior vice president, business development at Coulter, a biotechnology company focused on immunotherapeutic approaches to cancer, autoimmune and infectious diseases, where she completed numerous transactions including a $1.0 billion merger between Corixa and Coulter.  Ms. Morris began her career at Johnson & Johnson (J&J) as a sales representative rising to vice president of business development.  

Ms. Morris received her bachelor's degree in biology and chemistry from Carlow College. In addition to Syndax Ms. Morris serves on the board of directors of Neovacs, MediciNova and Humane Society of Silicon Valley.

About Syndax

Syndax Pharmaceuticals, Inc. is a Waltham, MA-based, oncology-focused pharmaceutical company. Syndax is building a portfolio of new oncology products to extend and improve the lives of patients by developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens. Syndax's lead product candidate is entinostat, an orally bioavailable, highly selective, class I histone deacetylase (HDAC) inhibitor with a long half-life that allows for weekly or every-other-week dosing. The robust clinical program for entinostat includes: a randomized, phase 2 clinical trial in patients with advanced non-small cell lung cancer that showed a survival advantage in a subset of the population, a completed randomized, placebo-controlled phase 2 trial in advanced breast cancer that will be presented later this year, nine ongoing trials in various cancers including advanced breast, non-small-cell lung cancer and  colorectal cancer and a pivotal program that is being planned for women with advanced metastatic estrogen-receptor positive breast cancer.  Formed in 2005 the company's intellectual property is based on work from scientific founder Ronald Evans, Ph.D., recipient of the 2004 Albert Lasker Prize for Basic Medical Research, a Member of the National Academy of Sciences, a professor at the Salk Institute for Biological Studies and a Howard Hughes Medical Institute Investigator.  Syndax has worldwide rights to develop and commercialize entinostat and is backed by top-tier Venture Capital firms: Domain Associates, MPM Capital, Avalon, Pappas and Forward Ventures.  For more information please visit www.syndax.com.

Contact Information
E. Blair Schoeb
Syndax Pharmaceuticals, Inc.
Tel: 908-277-0386
bschoeb@syndax.com


'/>"/>
SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
2. Syndax Pharmaceuticals to Present at Sachs Biotech in Europe Investor Forum
3. Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat
4. Syndax Pharmaceuticals Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients
5. Syndax Pharmaceuticals Entinostat in Combination Shows Activity in Breast Cancer
6. Syndax Pharmaceuticals to Present at Biotech Showcase 2011
7. Syndax Announces Publication of Entinostat NSCLC Data in Cancer Research
8. Syndax Announces Start of NCI Sponsored Phase 2 Study of Entinostat in Combination in Triple Negative Breast Cancer
9. Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting
10. Syndax Pharmaceuticals Announces Issuance of US Patent for Entinostat
11. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Feb. 22, 2017  Andre, DiMino, CEO of ADM ... manufacturer of innovative technologies and products, commented on ADMT,s ... February 21, 2017 in the Company,s quarterly report on ... ADMT CEO Andre, DiMino stated "During the quarter ended ... by devoting a larger portion of our engineering efforts ...
(Date:2/22/2017)... 22, 2017  Ultra Clean Holdings, Inc. (Nasdaq: ... systems and subsystems for the semiconductor capital equipment, ... reported its financial results for the fourth quarter ... "2016 was a year of extraordinary growth ... record highs and together with continued focus on ...
(Date:2/22/2017)... NEW YORK , Feb. 22, 2017 ... spinal cord partnering deals and agreements entered into by ... report: http://www.reportlinker.com/p03605680-summary/view-report.html Description The Global Spinal ... understanding and access to partnering deals and agreements entered ... - Trends in partnering deals - Top deals ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... ... absorption cannabidiol (CBD) serum, “NANOCALM 300” Microemulsified Hemp Extract. This premier nanoemulsified ... from the mouth into the bloodstream. Far outpacing the absorption speed ...
(Date:2/22/2017)... ... February 22, 2017 , ... ANGLESTRONG , the new recovery management app ... the App Store and Google Play . Florida-based Sober Network, Inc., ... recovery industry, partnered with Angle to build ANGLESTRONG. The new recovery management app is ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... launch of ProGen™ PRP, the latest innovation in the delivery of Platelet Rich ... care, aesthetics, cardiovascular and pain management, to accelerate tissue synthesis and provide a ...
(Date:2/22/2017)... ... February 22, 2017 , ... Forty-five percent of American ... that family members or friends have also commented about their poor hearing. However, ... hearing aids. One reason, suggested by 89 percent of American respondents, is that ...
(Date:2/22/2017)... ... February 22, 2017 , ... Pet obesity in the ... of dogs, according to the Association for Pet Obesity Prevention (APOP). During the ninth ... food issues such as the benefits of corn and grains, value of raw and ...
Breaking Medicine News(10 mins):